Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts

Biotech Jason Mast

Biotech turns to new and strange viruses to overcome gene therapy’s limitations

The hope is that nature’s nanoscale menagerie can be used to solve the safety, durability, and capacity issues in the gene therapy field.

Read The Story

Biotech Allison DeAngelis

Bayer’s venture arm ramps up, seeking to invest $1.3 billion

Biotech Jonathan Wosen

Researchers show they can quickly turn CAR-T cells on and off, raising hopes for safer cancer treatments

Biotech Jason Mast

After early wins, CRISPR gene editing is about to get a lot harder

Biotech Allison DeAngelis

New CRISPR startup, drawing big-name backers, seeks to fix diseases caused by large DNA errors

All Coverage

Biotech Megan Molteni

Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease

Health Lev Facher

The meth crisis is worse than ever, but new treatments might be around the corner

Biotech Allison DeAngelis

U.S. to spend more than $2 billion to launch Biden’s biomanufacturing initiative

Biotech Allison DeAngelis

Medical pioneers team up to launch new cell therapy biotech

Biotech Adam Feuerstein

Akero treatment for NASH reduces liver scarring, achieves goals of mid-stage study

Biotech Adam Feuerstein

Data likely support approval of Amgen’s KRAS-targeted drug, but still come with disappointments

Biotech Ryan Cross — The Boston Globe

Pretzel Therapeutics, eyeing diseases caused by broken mitochondria, launches with $72.5 million

Biotech Ryan Cross — The Boston Globe

Boston’s most valuable biotech? It’s not who you might expect

Biotech Jason Mast

Cancer treatment devised in the 1980s has proven effective (again). Will it finally get approval?

Biotech Damian Garde

Data show strong results for Alnylam therapy for heart disease, but magnitude of benefit will stir debate

Biotech Adam Feuerstein

In reversal, FDA advisers vote to support approval of Amylyx’s drug for ALS

Biotech Adam Feuerstein

Gilead drug prolongs survival of women with common form of breast cancer

Biotech Matthew Herper

Relay Therapeutics drug shows promise in early trial

Biotech Damian Garde

Roche pays $250 million to acquire Good Therapeutics and its preclinical cancer therapy

Matt's Take Matthew Herper

Why Illumina has a merger mess of its own making

Biotech Allison DeAngelis

Once a small player among biotech VCs, Mubadala Capital Ventures is punching above its weight

Heavyweights Damian Garde

For the ‘godfather’ of biotech, saving Biogen is the final act of a singular career

Matt's Take Matthew Herper

Moderna’s suing Pfizer? Wow! OK, now take a deep breath.

Biotech Jason Mast

Moderna sues Pfizer and BioNTech over Covid-19 vaccine

Biotech Jason Mast

How a long-overlooked protein could remake neuroscience drug discovery — or plunge the FDA into controversy

Biotech Isabella Cueto

Faster drug approval route sparks investment in rare kidney disease treatments

Biotech Kate Sheridan

OrbiMed tumbles from the top of STAT’s biotech venture capital performance ranking

Biotech Damian Garde

FDA approves Axsome’s fast-acting treatment for major depression

Biotech Ryan Cross — The Boston Globe

Biotech

Biotech turns to new and strange viruses to overcome gene therapy’s limitations

Bayer’s venture arm ramps up, seeking to invest $1.3 billion

Researchers show they can quickly turn CAR-T cells on and off, raising hopes for safer cancer treatments

After early wins, CRISPR gene editing is about to get a lot harder

New CRISPR startup, drawing big-name backers, seeks to fix diseases caused by large DNA errors

All Coverage

Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease

The meth crisis is worse than ever, but new treatments might be around the corner

U.S. to spend more than $2 billion to launch Biden’s biomanufacturing initiative

Medical pioneers team up to launch new cell therapy biotech

Akero treatment for NASH reduces liver scarring, achieves goals of mid-stage study

Data likely support approval of Amgen’s KRAS-targeted drug, but still come with disappointments

Pretzel Therapeutics, eyeing diseases caused by broken mitochondria, launches with $72.5 million

Boston’s most valuable biotech? It’s not who you might expect

Cancer treatment devised in the 1980s has proven effective (again). Will it finally get approval?

Data show strong results for Alnylam therapy for heart disease, but magnitude of benefit will stir debate

In reversal, FDA advisers vote to support approval of Amylyx’s drug for ALS

Gilead drug prolongs survival of women with common form of breast cancer

Relay Therapeutics drug shows promise in early trial

Roche pays $250 million to acquire Good Therapeutics and its preclinical cancer therapy

Why Illumina has a merger mess of its own making

Once a small player among biotech VCs, Mubadala Capital Ventures is punching above its weight

For the ‘godfather’ of biotech, saving Biogen is the final act of a singular career

Moderna’s suing Pfizer? Wow! OK, now take a deep breath.

Moderna sues Pfizer and BioNTech over Covid-19 vaccine

How a long-overlooked protein could remake neuroscience drug discovery — or plunge the FDA into controversy

Faster drug approval route sparks investment in rare kidney disease treatments

OrbiMed tumbles from the top of STAT’s biotech venture capital performance ranking

FDA approves Axsome’s fast-acting treatment for major depression

‘We’re finally here’: Harvard graduate spearheads custom gene therapy for younger brother

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day